4/2
11:07 pm
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $28.00.
Medium
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $28.00.
4/2
11:07 pm
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $28.00.
Medium
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $28.00.
3/1
06:20 pm
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) was upgraded by analysts at TheStreet from a "d+" rating to a "c" rating.
Medium
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) was upgraded by analysts at TheStreet from a "d+" rating to a "c" rating.
2/28
05:12 pm
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $28.00 price target on the stock.
Medium
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $28.00 price target on the stock.
2/28
05:12 pm
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $28.00 price target on the stock.
Medium
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $28.00 price target on the stock.